Haematology

2010

1. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial

   The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941

2. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

   European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328

3. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

   Blood, Vol. 116, Núm. 25, pp. 5650-5659

4. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation

   Annals of Oncology, Vol. 21, Núm. 9, pp. 1891-1897

5. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study

   Transfusion and Apheresis Science, Vol. 43, Núm. 3, pp. 299-303

6. El registro RIETE de pacientes con enfermedad tromboembólica venosa

   Galicia Clínica, Vol. 71, Núm. 2, pp. 53-55

7. ITER study of patients with haemo philia A and factor VIII inhibitors

   Hamostaseologie, Vol. 30, Núm. SUPPL.1, pp. 46-47

8. Neutrophilic dermatosis of the dorsal hands associated with a "myeloproliferative neoplasm, unclassifiable" and a simultaneous cancer of colon.

   Acta medica (Hradec Králové) / Universitas Carolina, Facultas Medica Hradec Králové, Vol. 53, Núm. 3, pp. 153-156

9. Non-genetic risk factors and the development of inhibitors in haemophilia: A comprehensive review and consensus report

   Haemophilia, Vol. 16, Núm. 5, pp. 747-766

10. Oligo-secretory myeloma in a patient with ankylosing spondylitis

    Rheumatology International, Vol. 30, Núm. 9, pp. 1227-1229

11. Pancitopenia extrema en una mujer joven

    Hematología práctica, Vol. 5, Núm. 3, pp. 47-49

12. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements

    Journal of Thrombosis and Haemostasis, Vol. 8, Núm. 5, pp. 1012-1017

13. Profilaxis y tratamiento de la infección fúngica invasora en el paciente neutropénico

    Revista Espanola de Quimioterapia, Vol. 23, Núm. 4, pp. 177-183

14. Prolonged travel and venous thromboembolism findings from the RIETE registry

    Thrombosis Research, Vol. 126, Núm. 4, pp. 287-291

15. Recommendations of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the prevention of invasive fungal infection due to filamentous fungi

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 28, Núm. 3

16. Relación entre presencia de comorbilidad y control del asma

    Archivos de Bronconeumologia, Vol. 46, Núm. 10, pp. 508-513

17. Sequential combined bypassing therapy of bleeds unresponsive to a single bypassing agent Safety and efficacy: Safety and efficacy

    Hamostaseologie, Vol. 30, Núm. SUPPL.1, pp. 54-55

18. The impact of bleeding history, von willebrand factor and PFA-100® on the diagnosis of type 1 von willebrand disease: Results from the european study MCMDM-1VWD

    British Journal of Haematology, Vol. 151, Núm. 3, pp. 245-251

19. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy

    Journal of Clinical Oncology, Vol. 28, Núm. 24, pp. 3872-3879

20. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD

    Thrombosis Research, Vol. 126, Núm. 3, pp. 227-231